NCT03525119 - Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine | Biotech Hunter

Enrollment

900

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

October 3, 2018

Study Completion Date

July 9, 2019

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

TDV

TDV SC injection

BIOLOGICAL

HAV Vaccine

HAV Vaccine IM injection.

BIOLOGICAL

TDV Placebo

Placebo-matching (normal saline (0.9% NaCl) SC injection.

BIOLOGICAL

HAV Vaccine Placebo

Placebo-matching (normal saline (0.9% NaCl) IM injection.

Trial Locations (10)

Synexus - Midlands, Edgbaston

Synexus - Lancashire, Chorley

Synexus - Merseyside, Waterloo

Royal Hallamshire Hospital, Sheffield

Synexus - Wales, Cardiff

Synexus - Scotland, Glasgow

North East Clinical Research Centre, Hexham General Hospital, Hexham

Synexus - Manchester, Manchester

Synexus - Thames Valley, Reading

North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees, Stockton-on-Tees